Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone Lymphoma.
C-X-C motif chemokine receptor 4
CXCR4
Chemokine receptor
Marginal zone lymphoma
Theranostics
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
09
02
2024
accepted:
18
07
2024
revised:
05
07
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
aheadofprint
Résumé
C-X-C motif chemokine receptor 4 (CXCR4)-directed molecular imaging provides excellent read-out capabilities in patients with marginal zone lymphoma (MZL). We aimed to determine the interobserver agreement rate of CXCR4-targeted PET/CT among readers with different levels of experience. 50 subjects with MZL underwent CXCR4-targeted PET/CT, which were reviewed by four readers (including two experienced and two less experienced observers). The following 8 parameters were investigated: overall scan result, CXCR4 density in lymphoma tissue, extranodal organ involvement, No. of affected extranodal organs and extranodal organ metastases, lymph node (LN) involvement and No. of affected LN areas and LN metastases. We applied intraclass correlation coefficients (ICC; < 0.4, poor; 0.4-0.59, fair; 0.6-0.74, good and > 0.74 excellent agreement rates). Among all readers, fair agreement was recorded for No. of affected extranodal organs (ICC, 0.40; 95% confidence interval [CI], 0.25-0.68), overall scan result (ICC, 0.42; 95%CI, 0.28-0.57), CXCR4 density in lymphoma tissue (ICC, 0.52; 95%CI, 0.38-0.66), and No. of extranodal organ metastases (ICC, 0.55; 95%CI, 0.41-0.61) and LN involvement (ICC, 0.59; 95%CI, 0.46-0.71). Good agreement rates were observed for No. of LN metastases (ICC, 0.71; 95%CI, 0.60-0.81) and No. of LN areas (ICC, 0.73; 95%CI, 0.63-0.82), while extranodal organ involvement (ICC, 0.35; 95%CI, 0.21-0.51) achieved poor concordance. On a reader-by-reader comparison, the experienced readers achieved significantly higher agreement rates in 4/8 (50%) investigated scan items (ICC, range, 0.21-0.90, P < / = 0.04). In the remaining 4/8 (50%), a similar trend with higher ICCs for the experienced readers was recorded (n.s.). CXCR4-directed PET/CT mainly provided fair to good agreement rates for scan assessment, while a relevant level of experience seems to be required for an accurate imaging read-out.
Identifiants
pubmed: 39090381
doi: 10.1007/s11307-024-01940-y
pii: 10.1007/s11307-024-01940-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Stollberg S, Kammerer D, Neubauer E, Schulz S, Simonitsch-Klupp I, Kiesewetter B, Raderer M, Lupp A (2016) Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. J Cancer Res Clin Oncol 142:2239–2247
doi: 10.1007/s00432-016-2220-6
pubmed: 27544389
Duell J, Buck AK, Hartrampf PE, Schlotelburg W, Schneid S, Weich A, Dreher N, Lapa C, Kircher M, Higuchi T, Samnick S, Serfling SE, Raderer M, Rasche L, Einsele H, Topp MS, Kosmala A, Werner RA (2023) Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma. J Nucl Med 64(12):1889–94
doi: 10.2967/jnumed.123.266074
pubmed: 37797975
Kosmala A, Seifert S, Schneid S, Dreher N, Higuchi T, Weich A, Serfling SE, Hartrampf PE, Einsele H, Buck AK, Topp MS, Duell J, Werner RA (2023) Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging. Mol Imaging Biol 25:758–764
doi: 10.1007/s11307-023-01830-9
pubmed: 37286923
pmcid: 10333359
Haug AR, Leisser A, Wadsak W, Mitterhauser M, Pfaff S, Kropf S, Wester HJ, Hacker M, Hartenbach M, Kiesewetter-Wiederkehr B, Raderer M, Mayerhoefer ME (2019) Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI. Theranostics 9:3653–3658
doi: 10.7150/thno.31032
pubmed: 31281504
pmcid: 6587159
Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE, Werner RA (2022) Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using (68)Ga-Pentixafor PET. J Nucl Med 63:1687–1692
pubmed: 35241482
Herhaus P, Habringer S, Vag T, Steiger K, Slotta-Huspenina J, Gerngross C, Wiestler B, Wester HJ, Schwaiger M, Keller U (2017) Response assessment with the CXCR4-directed positron emission tomography tracer [(68)Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. EJNMMI Res 7:51
doi: 10.1186/s13550-017-0294-z
pubmed: 28577295
pmcid: 5457373
Duell J, Krummenast F, Schirbel A, Klassen P, Samnick S, Rauert-Wunderlich H, Rasche L, Buck AK, Wester HJ, Rosenwald A, Einsele H, Topp MS, Lapa C, Kircher M (2021) Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. J Nucl Med 62:1415–1421
doi: 10.2967/jnumed.120.257279
pubmed: 33579803
Werner RA, Bundschuh RA, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP (2019) Novel Structured Reporting Systems for Theranostic Radiotracers. J Nucl Med 60:577–584
doi: 10.2967/jnumed.118.223537
pubmed: 30796171
pmcid: 6495242
Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Poppel TD, Rischpler C, Schwarzenbock S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M (2017) (68)Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med 58:1617–1623
doi: 10.2967/jnumed.117.190827
pubmed: 28408531
Grawe F, Ebner R, Geyer T, Beyer L, Winkelmann M, Sheikh GT, Eschbach R, Schmid-Tannwald C, Cyran CC, Ricke J, Bartenstein P, Heimer MM, Faggioni L, Spitzweg C, Fabritius MP, Auernhammer CJ, Ruebenthaler J (2023) Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients. Eur Radiol 33:3416–3424
doi: 10.1007/s00330-023-09518-y
pubmed: 36964768
pmcid: 10121493
Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, Buck AK, Bengel FM, Pomper MG, Gorin MA, Rowe SP (2020) (18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics 10:1–16
doi: 10.7150/thno.37894
pubmed: 31903102
pmcid: 6929634
Hartrampf PE, Kosmala A, Serfling SE, Bundschuh L, Higuchi T, Lapa C, Rowe SP, Matsusaka Y, Weich A, Buck AK, Bundschuh RA, Werner RA (2023) Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4-Directed Molecular Imaging and Therapy. Clin Nucl Med 48:483–488
doi: 10.1097/RLU.0000000000004629
pubmed: 36947793
pmcid: 10184817
Cicchetti D (1994) Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 6:284–290
doi: 10.1037/1040-3590.6.4.284
Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334
doi: 10.1007/BF02310555
Bland JM, Altman DG (1997) Statistics notes: Cronbach’s alpha. BMJ 314:572
doi: 10.1136/bmj.314.7080.572
pubmed: 9055718
pmcid: 2126061
Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Measur 20:37–46
doi: 10.1177/001316446002000104
Ashby D. (1991) Practical statistics for medical research. Douglas G. Altman, Chapman and Hall, London, 1991. No. of pages: 611. Price: £32.00. Stat Med. 10:1635-1636
Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M (2015) Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med 56:410–416
doi: 10.2967/jnumed.114.151647
pubmed: 25698782
Rivero A, Mozas P, Magnano L, Lopez-Guillermo A (2023) Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review. Front Oncol 13:1170394
doi: 10.3389/fonc.2023.1170394
pubmed: 37207160
pmcid: 10189145
Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, Pienta KJ, Gafita A, Hope TA, Pomper MG, Eiber M, Gorin MA (2023) Rowe SP. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 84:491–502
doi: 10.1016/j.eururo.2023.06.008
pubmed: 37414701
Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C (2018) SSTR-RADS Version 10 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J Nucl Med. 59:1085–1091
doi: 10.2967/jnumed.117.206631
pubmed: 29572257
Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M (2023) Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 83:405–412
doi: 10.1016/j.eururo.2023.02.002
pubmed: 36935345
Cheson BD (2007) The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 21:841–854
doi: 10.1016/j.hoc.2007.06.011
pubmed: 17908623
(n.a.) Eckert & Ziegler receives green light for phase III study with PENTIXAFOR. Pentixapharm. https://www.pentixapharm.com/news/qcqpd2zr93mqysmqsp8ve70mp6za11 . Accessed 15 Oct 2023